Severe COVID-19 patients were characterized by having an increased pro-apoptotic pathways in pDCs, lower level of TLR9 in pDCs, decrement in DHX36 expression in CLEC9a+ DCs, decreased expression of MHCII related gene in CD1c+ DCs and decrement of ISG in monocyte subsets [124]. This evidence concerns the gene CLEC9A and COVID-19.